The coronavirus pandemic notwithstanding, Curadev snares its second Sting partner.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.